Eurofins GeneticLab
28-196, Nishi 15, Kita 9 Jo,
Chuo-ku, Sapporo-shi,
Hokkaido 060-0009
Japan
Phone: +81 011-644-7301
Fax: +81 011-644-7611
sales@gene-lab.com
www.gene-lab.com
Get Directions
Eurofins Genetic Lab was established in September 2000 as the first industry-academia collaboration. Since its establishment in September 2000, Eurofins Genetic Labs has been measuring genes and proteins using state-of-the-art equipment. Since its establishment in September 2000 as the first industry-academia venture company from a national university, Eurofins Genetic Labs has been measuring genes and proteins using state-of-the-art equipment. We have been providing research support and contract analysis services to many universities, university hospitals, public research institutions, and pharmaceutical companies. In May 2003, we launched our pathological diagnosis business. We have been providing research support and contract analysis services mainly to many universities, university hospitals, public research institutions, and pharmaceutical companies. We also provide prompt diagnosis and report the results to our customers. In addition, we have also launched a service for integrated exploratory evaluation of biomarkers, which we call "molecular pathology analysis service," by integrating these two businesses. We also provide a contract service for integrated exploratory evaluation of biomarkers, which can be called a molecular pathology analysis service, integrating these two businesses. This service is, in addition to the technologies that Eurofins Genetic Labs has cultivated independently, this service is also supported by a large number of specialists and researchers, ranging from basic research to clinical studies, who have been involved in the development of the service. This service was developed based on the results of joint research with many specialists and researchers from basic research to clinical studies, in addition to the technology that Eurofins Genetic Lab has cultivated on its own. This new service is the third pillar of our business. This new service will be the third pillar of our business, and we will continue to develop new services in response to changes in diversified medical care, such as personalized medicine, which is expected to develop in the future. We aim to contribute to society by capturing the changes in diversified medical care, such as personalized medicine, which is expected to develop in the future, and to contribute to the treatment and diagnosis of patients.